Glutamine exerts a protective effect on osteoarthritis development by inhibiting the Jun N-terminal kinase and nuclear factor kappa-B signaling pathways
Open Access
- 13 July 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-9
Abstract
Strategies for treating osteoarthritis (OA) have become a research focus because an effective treatment for OA is unavailable. The objective of this study was to explore the effects and underlying mechanisms of glutamine (Gln) in OA. First, the chondrocytes were identified and a standard IL-1β-induced OA model was established. After treatment with Gln or saline, the viability and apoptosis of chondrocytes were evaluated using a CCK-8 assay and flow cytometry analysis, which revealed that Gln can improve the IL-1β-induced OA cells. Meanwhile, Gln can enhance the expression of aggrecan and collagen II, which are protective proteins for articular cartilage. Instead, Gln inhibited the expression of matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13), which can degrade cartilage. To better understand the underlying mechanisms of Gln in IL-1β-induced chondrocytes, the classical OA pathways of JNK and NF-κB were examined at the protein and mRNA levels using western blot and qRT–PCR analyses. We found that JNK and NF-κB were downregulated gradually depending on the Gln dose and protective and destructive factors changed based on changes of JNK and NF-κB. The effects of high-dose Gln were more effective than low-dose. Moreover, Gln was applied to the animal OA model to check the effects in vivo. The results showed that Gln attenuated cartilage degeneration and decreased OARSI scores, which demonstrated that Gln can improve OA. The experiments showed that Gln can benefit mice with OA by inhibiting the JNK and NF-κB signaling pathways.Keywords
Funding Information
- Natural Science Research Project of Colleges and Universities in Anhui Province (KJ2019A0261)
This publication has 50 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Glutamine Treatment Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced ColitisPLOS ONE, 2012
- Role of Interleukin-1 Inhibitors in OsteoarthritisDrugs & Aging, 2012
- p38/NF‐kB‐dependent expression of COX‐2 during differentiation and inflammatory response of chondrocytesJournal of Cellular Biochemistry, 2008
- The c-jun kinase/stress-activated pathway: Regulation, function and role in human diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS‐4 and ADAMTS‐5Arthritis & Rheumatism, 2007
- Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytesMatrix Biology, 2002
- Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in miceJournal of Clinical Investigation, 2001
- GlutamineBritish Journal of Surgery, 1996
- EFFECTS OF AN ANTI ULCER AGENT, N-ACETYL-L-GLUTAM1NE ALUMINUM COMPLEX (KW-110) ON THE DUODENAL AND GASTRIC ULCER MODELS IN THE RATThe Japanese Journal of Pharmacology, 1974